The study by Boos SL underlined the capacity of KRAS wild-type CRC organoids to simulate and reproduce gradual chemotherapy tolerance to the combination of irinotecan and EGFR inhibition in vitro [168]. This evidence concerns the gene KRAS and colorectal carcinoma.